Ranolazine Added to Amiodarone Facilitates Earlier Conversion of Atrial Fibrillation Compared to Amiodarone-Only Therapy
Ημερομηνία
2017Γλώσσα
en
Λέξη-κλειδί
Επιτομή
Background: Amiodarone (AMIO) is for many years effectively used to control ventricular rate during atrial fibrillation (AF) and to convert it into sinus rhythm. However, due to its delayed onset of action, ranolazine (RAN), a new antianginal agent with atrial-selective electrophysiologic properties, has recently been attempted as add-on therapy with AMIO to facilitate AF conversion. Methods: To establish the role of this combination therapy, we enrolled 173 consecutive patients (68 ± 10 years, 54% male) with recent-onset (<48-hour duration) AF who were eligible for pharmacologic cardioversion. Patients were randomized to intravenous AMIO (loading dose 5 mg/kg in 1 hour followed by 50 mg/h; n = 81), or AMIO plus a single oral dose of RAN 1 g (n = 92). Results: Mean left atrial diameter did not significantly differ between groups, AMIO and AMIO + RAN (4.2 ± 0.5 cm vs 4.1 ± 0.4 cm, P = 0.18). The AMIO + RAN group compared with the AMIO-only group showed significantly shorter time to conversion (8.6 ± 2.8 hours vs 19.4 ± 4.4 hours, P < 0.0001) and higher conversion rate at 24 hours (98% vs 58%, P < 0.001). Left ventricular ejection fraction did not markedly vary between the two groups and ranged within moderately reduced values. No serious clinically evident adverse effects were observed in any of the patients receiving either AMIO or the combination treatment. Conclusions: Our data demonstrate faster sinus rhythm restoration and enhanced conversion rate of AF after AMIO plus RAN in patients with preserved ejection fraction and left atrial size, implicating a synergistic effect of the two agents. © 2017 Wiley Periodicals, Inc.
Collections
Related items
Showing items related by title, author, creator and subject.
-
Ranolazine depresses conduction of rapid atrial depolarizations in a beating rabbit heart model
Aidonidis I., Simopoulos V., Stravela S., Dipla K., Stamatiou R., Hatziefthimiou A., Molyvdas P.-A. (2021)Purpose: Previous clinical studies have shown that ranolazine (RAN) added to amiodarone (AMIO) might accelerate the termination of recent-onset atrial fibrillation. This study was undertaken to delineate possible mechanisms ... -
Amiodarone plus Ranolazine for Conversion of Post-Cardiac Surgery Atrial Fibrillation: Enhanced Effectiveness in Reduced Versus Preserved Ejection Fraction Patients
Simopoulos V., Hevas A., Hatziefthimiou A., Dipla K., Skoularigis I., Tsilimingas N., Aidonidis I. (2018)Purpose: Ranolazine (RAN) added to amiodarone (AMIO) has been shown to accelerate termination of postoperative atrial fibrillation (POAF) following coronary artery bypass surgery in patients without heart failure (HF). ... -
Ranolazine Enhances the Antiarrhythmic Activity of Amiodarone by Accelerating Conversion of New-Onset Atrial Fibrillation After Cardiac Surgery
Simopoulos, V.; Tagarakis, G. I.; Daskalopoulou, S. S.; Daskalopoulos, M. E.; Lenos, A.; Chryssagis, K.; Skoularingis, I.; Molyvdas, P. A.; Tsilimingas, N. B.; Aidonidis, I. (2014)Ranolazine is a relatively novel antiischemic/antianginal compound with antiarrhythmic properties. We investigated its ability to shorten the time to conversion of postoperative atrial fibrillation (POAF) when added to ...